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1 |  INTRODUCTION
Bohring- Opitz syndrome (BOS, MIM #605039) is a rare and 
severe disease characterized mainly by intrauterine growth 
retardation, feeding difficulties, severe to profound develop-
mental delay, nonspecific brain abnormalities, microcephaly, 
flexion at the elbows with ulnar deviation and flexion of the 
wrists and metacarpophalangeal joints (known as BOS pos-
ture) and distinctive facial features.1 Heterozygous ASXL1 
truncating mutations have been identified as the main cause 
of BOS.1, 2 A recent publication 3 called the attention to the 
fact that mutations associated with BOS are also present in 
the ExAC (Exome Aggregation Consortium) database.4 As 
ASXL1 is one of the genes most commonly mutated during 
hematopoietic clonal expansion of cells, the authors hypoth-
esized that the presence of this mutation in public databases 
could be due to somatic mosaicism, and they could confirm 
the hypothesis by manual examination of the ExAC WES 
reads.
We have recently identified a new BOS case, in which 
Sanger sequencing of ASXL1 revealed the p.Gly646Trpfs*12 
mutation, also present in ExAC.
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Key Clinical Message
In line with a recent study showing that ASXL1 mutations found in the common 
population cannot be ruled out as pathogenic, we have identified the ASXL1 
p.Gly646Trpfs*12 mutation—present in 132 individuals in ExAC—as a very prob-
able cause of the disease in a Bohring- Opitz syndrome patient.
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significance
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2 |  CASE REPORT
The patient is a 4- year- old Turkish boy, only child of a 
healthy nonconsanguineous couple and born at term via 
normal vaginal delivery after an uneventful pregnancy. 
The birthweight was 2.3 kg (1st percentile, −2.4 SD), 
height was 45 cm (−2.3 SD), and head circumference was 
32 cm (4th percentile, −1.7 SD). The patient was referred 
to the genetics department at the 9th day of life. Physical 
examination revealed trigonocephaly, microcephaly, nevus 
simplex (flammeus), dysmorphic features, intrauterine 
growth retardation, and BOS posture with fixed contrac-
tures. In the postnatal period, the patient was intubated 
due to respiratory problems. As he could not be extubated, 
at 4 months tracheostomy was performed. He was fed 
through G tube since the 4th month of life. At 2 months of 
age, the patient started suffering seizures. Abnormalities 
were detected by EEG, and antiepileptic treatment with le-
vetiracetam and phenobarbital was initiated. Seizures have 
been under control thereafter with 3- 4 attacks annually of 
a very short duration.
At 15 months, his weight was 10 kg (24th percentile, 
−0.69 SD), height was 62 cm (<3rd percentile, −5.4 SD), 
and head circumference was 41.5 cm (<1st percentile, −4.25 
SD). At 3.5 years, he had microcephaly (45.5 cm; <3rd per-
centile, −2.43 SD), trigonocephaly, up- slanting palpebral 
fissures, narrow forehead, nevus simplex, hypertrichosis, 
low- set ears, low frontal hairline, microretrognathia, high 
palate and delayed teeth eruption (no eruption at 3 years of 
age; Figure 1A,B). He also had bilateral cryptorchidism and 
brachydactyly (Figure 1C), as well as hypotonia and spasticity 
on both his upper and lower extremities. In particular, the pa-
tient had contractures of the hands and fingers. Additionally, 
overlapping toes were detected in the feet (Figure 1D). 
Cranial magnetic resonance revealed corpus callosum agen-
esis and atrophy of the optic nerve, and he failed the hearing 
test bilaterally. The patient also underwent echocardiography, 
which revealed a small patent ductus arteriosus. Abdominal 
ultrasound and metabolic tests were normal. The patient’s de-
velopmental milestones were severely delayed (he was not 
able to sit, crawl or walk independently and he was not able to 
speak). His karyotype and aCGH results were normal.
After reviewing the clinical presentation of the patient, 
Bohring- Opitz syndrome was suspected, and the ASXL1 
gene was manually sequenced. Written informed consent 
from the patient’s family was obtained, and all protocols 
were approved by the Ethics Committee of the Universitat 
de Barcelona (IRB00003099). A de novo heterozygous 
F I G U R E  1  Facial, hand and foot phenotypes of the patient at 3 y of age. A and B, Facial dysmorphisms, especially trigonocephaly and nevus 
simplex (flammeus) is clearly appreciated. C, brachydactyly is appreciable in the patient’s hand. D, Foot phenotype with overlapping toes
(A)
(C) (D)
(B)
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mutation, c.1934dupG (p.Gly646Trpfs*12), was identified. 
The PCR amplification and Sanger sequencing were repeated 
twice, independently and the PCR fragment was cloned and 
sequenced (see Figure S1) to unequivocally confirm the 
mutation.
3 |  DISCUSSION
While the clinical outcome of the patient clearly pointed to a 
Bohring-Opitz Syndrome, the fact that he was carrying a mu-
tation (p.Gly646Trpfs*12) present in 132 individuals from 
the general population hindered taking a final decision on the 
genetic diagnosis. In this sense, other mutations present in 
ExAC (among them the p.Arg404Ter described by Carlston 
et al3) were previously found to be BOS - causing (Table 1). 
The p.Gly646Trpfs*12 mutation described in our BOS case 
is one of the two ASXL1 loss of function (LoF) changes espe-
cially frequent in ExAC, the other being p.Gly645Valfs*58 
(found in 118 individuals). Both changes are located in an 
eight- nucleotide G- homopolymer tract and could be over- 
represented due to sequencing errors. While these changes 
were not included in Carlston et al3 analyses, the authors 
discussed the fact that the p.Gly646Trpfs*12 mutation had 
been identified in a large series of myeloid malignancies by 
deep sequencing (confirmed by manual methods in some 
cases) and had been described as the most common cancer- 
associated ASXL1 mutation.5 Besides, 66% of the ExAC car-
riers of the p.Gly646Trpfs*12 mutation belong to the Cancer 
Genome Atlas (TCGA) population.
This mutation is a truncating mutation affecting the last 
exons of the ASXL1 gene, similarly to all the previously de-
scribed BOS mutations (Figure 2). More recently, the p.Gly-
646Trpfs*12 mutation has been filtered from the GnomAD 
T A B L E  1  BOS- causing ASXL1 mutations present in ExAC
cDNA mutation Prot. mutation Reported phenotype ExAc GenomAD Origen
c.1117C>T p.Q373* Focal Epilepsya no 2/246256 6
c.1129C>T p.Q377* IDa no no 7
c.1210C>T p.R404* Bohring- Opitz syndrome 7/121378 4/246248 2, 3, 8, 9
c.1269dupT p.L424fs Bohring- Opitz syndrome no no 10
c.1272_1273delGT p.T425Qfs*12 Bohring- Opitz syndrome no 1/246262 1
c.1544_1545delTG p.V515Gfs*13 Focal Epilepsya no no 6
c.1924 G>T p.G642* Bohring- Opitz syndrome no no 1
c.1934insG p.G646Wfs*12 Bohring- Opitz syndrome 132/80804 nob Present 
study
c.2013_2014 del p.C672Tfs*4 Bohring- Opitz syndrome no no 1
c.2036_2037insG p.G680Rfs*38 Bohring- Opitz syndrome no no 11
c.2100dupT p.P701Sfs*16 Bohring- Opitz syndrome no no 12
c.2197C>T p.Q733* Bohring- Opitz syndrome 1/121070c idem ExAC 2
c.2324 T>G, p.L775* Bohring- Opitz syndrome 1/121162 nob 1
c.2332C>T p.Q778* Bohring- Opitz syndrome no no 2
c.2407_2411del5 p.Q803Tfs*17 Bohring- Opitz syndrome 3/120748c nob,c 2
c.2468T>G p.L823* Bohring- Opitz syndrome 2/120758c 2/244338c 2
c.2535dup p.S846Qfs*5 Bohring- Opitz syndrome no no 1
c.2759_2762dup p.V922Ifs*3 Bohring- Opitz syndrome no no 1
c.2773C>T p.Q925* Bohring- Opitz syndrome no no 2
c.2893C>T p.R965* Bohring- Opitz syndrome 1/121306 3/246200 13
c.3077del p.G1026Dfs*21 Bohring- Opitz syndrome no no 1
c.3083C>A p.S1028* Bohring- Opitz syndrome no no 2
c.4060 G>T p.E1354* Bohring- Opitz syndrome no no 14
c.4116_4117del2 p.F1373fs Bohring- Opitz syndromed no no 15
aClinical history is limited without description of presence or absence of other BOS features.
bFiltered in GenomAD (failed random forest filters).
cThese numbers correspond to another mutation affecting the same residue.
dThe patient is also carrying recessive mutations in the CFTR gene.
Bold type indicates the mutation in the case presented here
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database as it failed random forest filters. In addition, very 
recently a new patient with this mutation was reported to 
ClinVar by GenDX, although the clinical outcome of the pa-
tient was not reported.
Taking all this into consideration, we conclude that the 
p.Gly646Trpfs*12 mutation is a disease- causing mutation 
responsible for the patient’s BOS clinical presentation and 
that, as Carlston et al3 stated, the assumption that pathogenic 
variants in genes associated with severe, pediatric- onset, 
highly penetrant, autosomal dominant conditions have to be 
absent or extremely rare in public databases has to be taken 
cautiously.
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